PATENT CLAIM ANALYSIS

Application Number: 16090288
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "316000"]

Abstract:
In accordance with the present invention, the immunoregulatory activity of low doses of P 4 N was investigated. Unlike previously described antitumor drugs, low dose P 4 N, in doses of about 1 to 10 mg/kg, or at concentrations of about 10 to 100 nM, was surprisingly found to contribute to humoral immunity by raising the titers and activities of autoantibodies against GRP78 and F1F0 ATP synthase on the surface of CT26 cells, and inducing B cell proliferation and differentiation of plasma cells. Methods for inducing endogenous antitumor autoantibodies (EAA) in a subject having a neoplasia comprising administering to the subject an effective amount of the nordihydroguaiaretic acid (NDGA) derivative P4N, or salts, solvates and stereoisomers thereof, as well as methods for inducing B cell proliferation, inducing BAFF stimulated B cell proliferation, and suppressing or inhibition growth of a neoplasia are also provided.

Claim (Index 26):
The method of  claim 25 , wherein the cancer is colorectal cancer.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 97.0
- Lexical Diversity: 1.67708
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14755989', '12614283', '13524396', '11552686', '14779276']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7513930801062727
- 35 USC 102 Novelty (BERT): 0.5025064068350203
- Combined Prediction Score: 0.7265044127791475
- Mean Citation Score: 193.634008
- Max Citation Score: 204.52855
- Similarity Product: 130.43450469880105

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test